IPO-Bound Tryfacta Secures NIH Healthcare Staffing Contract Ahead of GIFT City Listing
June 17, 2026: IPO-bound Tryfacta, Inc., a US-based AI-enabled provider of specialized staffing and technology solutions, has announced that it has secured a healthcare staffing contract from the National Institutes of Health (NIH) to support operations in Maryland, United States.
The latest contract win marks a significant milestone for the company as it prepares for its proposed public listing on the GIFT City exchanges in India.
Strengthening Presence in Federal Healthcare Staffing
According to the company, the contract will support NIH operations in Maryland and further expand Tryfacta's footprint in the U.S. federal healthcare staffing sector.
The deal highlights the company's ability to provide mission-critical workforce solutions to government agencies and reinforces its position in the healthcare staffing market.
First US-Headquartered Company to List in India?
Tryfacta has already filed its prospectus for a proposed initial public offering (IPO) on the GIFT City exchanges.
Upon successful listing, the company is expected to become the first US-headquartered company to go public in India through GIFT City, marking a landmark development in cross-border capital markets.
AI-Enabled Staffing and Technology Solutions
Tryfacta specializes in:
-
Healthcare staffing solutions.
-
Government workforce management.
-
AI-enabled talent acquisition and technology services.
-
Specialized staffing for mission-critical sectors.
The company has been expanding its presence in federal and healthcare-related staffing assignments across the United States.
Key Highlights
-
Contract Awarded By: National Institutes of Health (NIH)
-
Location: Maryland, United States
-
Sector: Healthcare Staffing
-
Company: Tryfacta, Inc.
-
IPO Status: Prospectus filed for proposed GIFT City listing
-
Significance: Could become the first US-headquartered company to list in India via GIFT City
Strategic Milestone Ahead of IPO
The NIH contract comes at a crucial juncture for Tryfacta as investors closely track the company's proposed public issue.
Winning a contract from one of the most prominent healthcare research institutions in the United States is expected to enhance the company's credentials and strengthen its growth narrative ahead of the IPO.
